"Designing Growth Strategies is in our DNA"

Ophthalmic Disease Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, & Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), & Regional Forecast, 2024-2032

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI100441

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2023
    2. Pipeline Analysis, By Key Players
    3. Patent Snapshot, By Key Players
    4. Key Industry Developments – Merges, Acquisitions and Partnerships
    5. Regulatory Scenario for Key Countries
    6. Reimbursement Scenario for Key Countries
    7. Impact of COVID-19 on the Market
  5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. U.K
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semisolid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2023)
    2. Company Profiles
      1. Viatris Inc.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Novartis AG
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. AbbVie Inc.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. F. Hoffmann-La Roche Ltd.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Regeneron Pharmaceuticals, Inc.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Santen Pharmaceutical Co., Ltd.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Bayer AG
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Bausch & Lomb Incorporated
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Merck KGaA
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: Global Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2023 & 2032

Figure 2: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023 & 2032

Figure 3: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023 & 2032

Figure 4: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023 & 2032

Figure 5: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023 & 2032

Figure 6: Global Ophthalmic Disease Therapeutics Market Value (USD billion), by Region, 2023 & 2032

Figure 7: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 8: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023

Figure 9: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2023 & 2032

Figure 10: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023

Figure 11: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2023 & 2032

Figure 12: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023

Figure 13: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 14: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023

Figure 15: North America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country, 2023 & 2032

Figure 16: North America Ophthalmic Disease Therapeutics Market Value Share (%), By Country, 2023

Figure 17: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 18: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023

Figure 19: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2023 & 2032

Figure 20: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023

Figure 21: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2023 & 2032

Figure 22: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023

Figure 23: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 24: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023

Figure 25: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 26: Europe Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2023

Figure 27: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 28: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023

Figure 29: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2023 & 2032

Figure 30: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023

Figure 31: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2023 & 2032

Figure 32: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023

Figure 33: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 34: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023

Figure 35: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 36: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2023

Figure 37: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 38: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023

Figure 39: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2023 & 2032

Figure 40: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023

Figure 41: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2023 & 2032

Figure 42: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023

Figure 43: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 44: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023

Figure 45: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 46: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2023

Figure 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2023

Figure 49: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2023 & 2032

Figure 50: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2023

Figure 51: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2023 & 2032

Figure 52: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2023

Figure 53: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 54: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2023

Figure 55: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 56: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2023

Figure 57: Global Ophthalmic Disease Therapeutics Market Share (%), By Company, 2023

Table 1: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 2: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 3: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 4: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 5: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 6: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 7: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 8: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032

Table 9: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 10: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 11: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 12: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 13: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 14: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 15: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 16: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032

Table 17: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 18: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 19: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 20: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 21: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 22: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 23: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 24: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 25: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 26: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 27: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 28: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 29: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 30: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 31: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 32: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 33: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 34: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 35: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 36: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 37: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 38: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 39: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 40: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 41: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032

Table 42: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2032

Table 43: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2032

Table 44: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2032

Table 45: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2032

Table 46: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2032

Table 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032

Table 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Ophthalmic Disease Therapeutics Market Size, Share and Global Industry Trend Forecast till 2032
  • 2019-2032
  • 2023
  • 2019-2022
  • 180
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase